Sublingual versus vaginal misoprostol (400 μg) for cervical priming in first-trimester abortion: a randomized trial
2006; Elsevier BV; Volume: 74; Issue: 4 Linguagem: Inglês
10.1016/j.contraception.2006.03.031
ISSN1879-0518
AutoresJosep Lluís Carbonell Esteve, José María Navarro‐Marí, F. Carrión Valero, Margardel Llorente, I Ruiz Salvador, L. Varela, Pedro Lucena Leal, Ana Candel, Ana Tudela, María José Serrano, E. Muñoz,
Tópico(s)Maternal and fetal healthcare
ResumoObjective Our objective was to compare the sublingual administration and the vaginal administration of misoprostol for cervical priming before first-trimester surgical abortion. Design We used an open, multicenter, randomized trial. Locations We conducted the study in four clinics (in Valencia, Castell��, Murcia and Murcia Capital) in Spain. Participants A total of 1424 healthy pregnant women with amenorrhea of ���84 days who voluntarily decided to terminate their pregnancy participated in the study. Methods Women were randomly assigned to receive a single dose of 400 ��g of misoprostol either sublingually or vaginally 1���3 h before aspiration. Outcome Measures The outcome measures assessed were cervical dilation before surgery and surgical time needed for aspiration. The incidence of side effects, such as nausea, vomiting, diarrhea, fever/chills and paresthesia, was evaluated. Results The mean cervical dilation achieved was 6.8��0.8 and 6.7��0.9 mm for the sublingual and vaginal groups, respectively. The mean surgical time was 7.0��2.8 and 7.4��2.5 min for the sublingual and vaginal groups, respectively. Nausea, vomiting and diarrhea were more frequent in the sublingual group. Conclusions Both regimens had equal efficacy; however, the sublingual route caused more side effects.
Referência(s)